HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Cocrystal Pharma but lowered the price target from $10 to $7, indicating a more cautious outlook on the stock.
August 22, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Cocrystal Pharma but lowered the price target from $10 to $7, suggesting a more cautious outlook on the stock.
The maintenance of a Buy rating suggests continued confidence in Cocrystal Pharma's potential, but the lowered price target indicates a more cautious outlook, possibly due to revised expectations or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100